Twist Bioscience reported revenue growth compared to the industry average and its technology is noted for potentially replacing current computers.
2 reports, 2 independent
Updated Aug 7
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Twist Bioscience reported revenue growth compared to the industry average and its technology is noted for potentially replacing current computers.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Twist Bioscience
Biotechnology company
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.
- VUG concentrates on large-cap leaders like Nvidia. VUG holds large-cap leaders such as Microsoft. VUG holds established giants including Apple. IWO holds small-cap equities including Twist Bioscience.
Coverage
Newest first; wire copies grouped- Simply Wall St.Twist Bioscience Third Quarter 2025 Earnings: EPS Beats Expectations Explore Twist Bioscience's Fair Values from the Community and select yours Revenue: US$96.1m (up 18% from 3Q 2024). Net income: U
- GuruFocus.comTwist Bioscience Corp (TWST) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ... Revenue: $96.1 million, an increase of 18% year-over-year. Gross Margin: 53.4%, up from 43.3% in the th